Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B treatment Trial.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Effects of all-trans retinoic acid (ATRA) in addition to chemotherapy for adults with acute myeloid leukaemia (AML) (non-acute promyelocytic leukaemia (non-APL)).The Cochrane database of systematic reviews · 2018
   Pooled it
2. Randomized phase-III study of low-dose cytarabine and etoposide + /- all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia.Scientific reports · 2023
   Trial
3. FDA Approval Summary: Oral Azacitidine for Continued Treatment of Adults with Acute Myeloid Leukemia Unable to Complete Intensive Curative Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
   Trial
4. Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria.Haematologica · 2011
   Trial
5. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.Haematologica · 2009
   Trial
6. Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia.Leukemia · 2008
   Trial
7. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.Blood advances · 2020
   Article
8. GPR56 contributes to the development of acute myeloid leukemia in mice.Leukemia · 2016
   Article
9. Post-remission therapy for acute myeloid leukemia.Haematologica · 2014
   Review
10. Acute myeloid leukemia in the elderly: do we know who should be treated and how?Leukemia & lymphoma · 2014
    Review
11. Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance.Leukemia · 2013
    Article
12. Treatment of acute myeloid leukemia with 20-30% bone marrow blasts.Mediterranean journal of hematology and infectious diseases · 2013
    Article
13. Acute myeloid leukemia in older adults.International journal of hematology · 2012
    Review
14. Genetic abnormalities and challenges in the treatment of acute myeloid leukemia.Genes & cancer · 2011
    Article
15. A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China.Journal of hematology & oncology · 2009
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

22 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as